|
PT90657B
(pt)
|
1988-05-27 |
1995-03-01 |
Ortho Pharma Corp |
Processo para a preparacao de peptidos que bloqueiam a ligacao de hiv-1 a proteina cd4 receptora
|
|
JPH0768273B2
(ja)
*
|
1988-12-02 |
1995-07-26 |
カルピス食品工業株式会社 |
抗ｈｉｖペプチド
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
|
WO1990013562A1
(en)
|
1989-05-02 |
1990-11-15 |
Genelabs Incorporated |
Chemically modified cd4 peptide fragments having anti-retroviral properties
|
|
US5690933A
(en)
|
1989-05-31 |
1997-11-25 |
Glaxo Wellcome Inc. |
Monoclonal antibodies for inducing tolerance
|
|
GB8912497D0
(en)
|
1989-05-31 |
1989-07-19 |
Cobbold Stephen P |
Monoclonal antibodies
|
|
US20020099179A1
(en)
|
1989-12-21 |
2002-07-25 |
Linda K. Jolliffe |
Cdr-grafted antibodies
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
HUT60768A
(en)
|
1990-03-16 |
1992-10-28 |
Sandoz Ag |
Process for producing cd25 fixing molecules
|
|
US7084260B1
(en)
|
1996-10-10 |
2006-08-01 |
Genpharm International, Inc. |
High affinity human antibodies and human antibodies against human antigens
|
|
JPH05505112A
(ja)
|
1990-11-27 |
1993-08-05 |
バイオジェン，インコーポレイテッド |
Ａｉｄｓ、ａｒｃおよびｈｉｖ感染の予防および治療に有用な抗ｃｄ４抗体ホモログ
|
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
|
US6136310A
(en)
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
|
JPH05244982A
(ja)
|
1991-12-06 |
1993-09-24 |
Sumitomo Chem Co Ltd |
擬人化ｂ−ｂ１０
|
|
US5777085A
(en)
|
1991-12-20 |
1998-07-07 |
Protein Design Labs, Inc. |
Humanized antibodies reactive with GPIIB/IIIA
|
|
IL101769A
(en)
|
1992-05-03 |
2007-02-11 |
Yeda Res & Dev |
Modulation of TNF receptor action
|
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
|
WO1995009652A1
(en)
|
1993-10-06 |
1995-04-13 |
The Kennedy Institute For Rheumatology |
Treatment of autoimmune and inflammatory disorders
|
|
ATE155043T1
(de)
|
1992-10-08 |
1997-07-15 |
Kennedy Inst Of Rheumatology |
Behandlung von autoimmun- und entzundungskrankheiten
|
|
DE69427928T3
(de)
|
1993-03-05 |
2012-05-10 |
Bayer Healthcare Llc |
Humane monoklonale anti-TNF alpha Antikörper
|
|
EP0631783A1
(en)
|
1993-06-03 |
1995-01-04 |
Mitsubishi Chemical Corporation |
Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
|
|
US20020068057A1
(en)
|
1994-03-10 |
2002-06-06 |
Marc Feldmann |
Treatment of autoimmune and inflammatory disorders
|
|
WO1996036359A1
(en)
|
1995-05-18 |
1996-11-21 |
Ortho Pharmaceutical Corporation |
Induction of immunological tolerance by the use of non-depleting anti-cd4 antibodies
|
|
DE122004000004I1
(de)
|
1996-02-09 |
2004-08-12 |
Abott Biotechnology Ltd |
Humane Antikörper welche an Humanen TNFalpha binden.
|
|
US20010056066A1
(en)
|
1996-07-26 |
2001-12-27 |
Smithkline Beecham Corporation |
Method of treating immune cell mediated systemic diseases
|
|
EP0946195A1
(en)
|
1996-10-01 |
1999-10-06 |
Celltech Therapeutics Limited |
Pharmaceutical products containing protein-tyrosine kinase inhibitors and anti-cd4 antibodies
|
|
US6037454A
(en)
|
1996-11-27 |
2000-03-14 |
Genentech, Inc. |
Humanized anti-CD11a antibodies
|
|
DE19722888A1
(de)
|
1997-05-28 |
1998-12-03 |
Thomas Prof Dr Huenig |
Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten
|
|
WO2000058362A1
(en)
|
1999-03-26 |
2000-10-05 |
Human Genome Sciences, Inc. |
Neutrokine-alpha binding proteins and methods based thereon
|
|
EP1194167B1
(en)
|
1999-06-09 |
2009-08-19 |
Immunomedics, Inc. |
Immunotherapy of autoimmune disorders using antibodies which target b-cells
|
|
US7304127B2
(en)
|
1999-08-27 |
2007-12-04 |
United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use
|
|
WO2001016182A2
(en)
*
|
1999-08-27 |
2001-03-08 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
POLYPEPTIDES THAT BIND HIV gp120 AND RELATED NUCLEIC ACIDS, ANTIBODIES, COMPOSITIONS, AND METHODS OF USE
|
|
CA2410786A1
(en)
|
2000-06-02 |
2001-12-13 |
Regents Of The University Of Minnesota |
Immunotherapeutic method to prevent islet cell rejection
|
|
US20020058029A1
(en)
|
2000-09-18 |
2002-05-16 |
Nabil Hanna |
Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
|
|
DE10050935A1
(de)
|
2000-10-11 |
2002-05-02 |
Tegenero Gmbh |
Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
|
|
EP1351681B1
(en)
|
2001-01-16 |
2010-09-15 |
Vascular Therapies, LLC |
Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
|
|
NZ528250A
(en)
|
2001-03-07 |
2006-09-29 |
Childrens Medical Center |
Method to screen peptide display libraries using minicell display
|
|
EP1241249A1
(en)
|
2001-03-12 |
2002-09-18 |
Gerold Schuler |
CD4+CD25+regulatory T cells from human blood
|
|
EP1381384B1
(en)
|
2001-04-24 |
2011-05-25 |
Merck Patent GmbH |
COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha
|
|
DE60238533D1
(de)
|
2001-06-14 |
2011-01-20 |
Cambridge Entpr Ltd |
Nicht-depletierender Antikörper TRX-1 gegen CD4 und dessen Verwendungen
|
|
US7541443B2
(en)
|
2001-06-14 |
2009-06-02 |
Tolerrx, Inc. |
Anti-CD4 antibodies
|
|
GB2376466A
(en)
|
2001-06-14 |
2002-12-18 |
Mark Frewin |
TRX1 antibody
|
|
ES2392287T3
(es)
|
2001-12-04 |
2012-12-07 |
Theramab Llc |
Péptido o proteína que contiene un bucle C'-D de la familia de receptores de la CD28
|
|
DE10212108A1
(de)
|
2002-03-13 |
2003-10-02 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
|
|
DE10230223A1
(de)
|
2002-07-04 |
2004-01-22 |
Tegenero Ag |
Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
|
|
JP2006515165A
(ja)
|
2002-09-16 |
2006-05-25 |
ジェネンテック・インコーポレーテッド |
免疫関連疾患の治療のための新規組成物と方法
|
|
US7388079B2
(en)
*
|
2002-11-27 |
2008-06-17 |
The Regents Of The University Of California |
Delivery of pharmaceutical agents via the human insulin receptor
|
|
US7501494B2
(en)
|
2003-01-15 |
2009-03-10 |
United Biomedical, Inc. |
Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
|
|
EP1460088A1
(en)
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanized anti-CD4 antibody with immunosuppressive properties
|
|
EP2062916A3
(en)
|
2003-04-09 |
2009-08-19 |
Genentech, Inc. |
Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
|
|
GB0314461D0
(en)
|
2003-06-20 |
2003-07-23 |
Isis Innovation |
Suppression of transplant rejection
|
|
AU2003264100A1
(en)
|
2003-08-25 |
2005-03-10 |
Pieris Proteolab Ag |
Muteins of a bilin-binding protein with affinity for a given target
|
|
EP1600164A3
(de)
|
2003-09-22 |
2006-05-17 |
TeGenero AG |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
|
|
DE10352900A1
(de)
|
2003-11-11 |
2005-06-16 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
|
|
BRPI0512017A
(pt)
|
2004-06-22 |
2008-02-06 |
Tolerrx Inc |
dosagem otimizada com anticorpos anti-cd4 para indução de toleráncia em primatas
|
|
CN101010342A
(zh)
|
2004-07-02 |
2007-08-01 |
健泰科生物技术公司 |
用于治疗非何杰金淋巴瘤的组合物和方法
|
|
US20070270431A1
(en)
|
2004-09-29 |
2007-11-22 |
Kowa Co., Ltd. |
Preventive and/or Therapeutic Medicine for Rheumatoid Arthritis
|
|
PT2171060E
(pt)
|
2004-11-11 |
2013-11-18 |
Theramab Llc |
Anticorpo anti-cd28 superagonista
|
|
US8119589B2
(en)
|
2004-11-12 |
2012-02-21 |
University Of North Carolina At Charlotte |
Modulation of CD4+ T cell responses by a tick saliva protein, Salp15 and polypeptides derived therefrom
|
|
DE102004063494A1
(de)
|
2004-12-23 |
2006-07-13 |
Tegenero Ag |
Antikörper
|
|
JP4730733B2
(ja)
|
2005-05-02 |
2011-07-20 |
国立大学法人京都大学 |
４型葉酸受容体の発現を指標とした制御性ｔ細胞の検出方法、及び免疫賦活剤
|
|
CA2614640A1
(en)
|
2005-07-11 |
2007-01-18 |
Macrogenics, Inc. |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
|
DE602006019977D1
(de)
|
2005-08-18 |
2011-03-17 |
Genmab As |
Therapie mit anti-cd4-antikörpern und bestrahlung
|
|
TWI478940B
(zh)
|
2005-08-26 |
2015-04-01 |
Roche Glycart Ag |
具有經改變細胞傳訊活性之改質抗原結合分子
|
|
SI1973950T1
(sl)
|
2006-01-05 |
2015-01-30 |
Genentech, Inc. |
Anti-EphB4 protitelesa in postopki njihove uporabe
|
|
KR20080112300A
(ko)
|
2006-03-16 |
2008-12-24 |
제넨테크, 인크. |
Ｃｄ4 항체를 사용하여 루푸스를 치료하는 방법
|
|
US8278421B2
(en)
*
|
2006-03-20 |
2012-10-02 |
Xoma Techolology Ltd. |
Human antibodies specific for gastrin materials and methods
|
|
WO2007117602A2
(en)
|
2006-04-07 |
2007-10-18 |
Biogen Idec Ma Inc. |
Isolation and use of human regulatory t cells
|
|
US8945564B2
(en)
|
2006-04-21 |
2015-02-03 |
Novartis Ag |
Antagonist anti-CD40 antibody pharmaceutical compositions
|
|
WO2007135684A2
(en)
*
|
2006-05-22 |
2007-11-29 |
Hadasit Medical Research Services & Development Limited |
Method of treatment of anti-cd4 autoimmunity
|
|
EP2109770B1
(en)
|
2007-02-01 |
2016-07-06 |
Universitätsmedizin der Johannes Gutenberg-Universität Mainz |
Specific activation of a regulatory T cell and its use for treatment of asthma, allergic disease, autoimmune disease, graft rejection and for tolerance induction
|
|
WO2008134046A1
(en)
|
2007-04-27 |
2008-11-06 |
Genentech, Inc. |
Potent, stable and non-immunosuppressive anti-cd4 antibodies
|
|
CN102027016A
(zh)
*
|
2008-03-13 |
2011-04-20 |
生物测试股份公司 |
一种治疗疾病的试剂
|
|
EP2265643B1
(en)
|
2008-03-13 |
2016-10-19 |
Biotest AG |
Dosing regimen for treating psoriasis and rheumatoid arthritis
|
|
RU2540018C2
(ru)
*
|
2008-03-13 |
2015-01-27 |
Биотест Аг |
Средство для лечения заболевания
|
|
EP2101173A1
(en)
|
2008-03-14 |
2009-09-16 |
Vivalis |
In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein
|
|
WO2010022341A1
(en)
|
2008-08-21 |
2010-02-25 |
The United State Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of enriching and using regulatory t cells
|
|
ES2335381B1
(es)
|
2008-09-24 |
2011-02-28 |
Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron |
Metodo in vitro y kit para el pronostico o prediccion de la respuestapor parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor tnfalfa.
|
|
BRPI0919489A2
(pt)
|
2008-09-29 |
2015-12-01 |
Biotest Ag |
composição, kit, métodos de tratamento de uma doença reumática, e de artrite reumatóide em um paciente, agente capaz de ativar células t reguladoras cd4+cd25+ e metotrexato, e, uso de um agente capaz de ativar células t reguladoras cd4+cd25+ e metotrexato
|
|
ES2351456B1
(es)
|
2009-06-24 |
2011-11-28 |
Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron |
Metodo in vitro para el pronostico o prediccion de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes que reconocen el receptor de membrana cd20 de los linfocitos b
|
|
JP5399219B2
(ja)
|
2009-11-24 |
2014-01-29 |
株式会社ケイティーバイオ |
関節リウマチに対するヒト型抗ＴＮＦα抗体薬の薬効予測方法、及び薬効予測装置
|
|
WO2011158798A1
(ja)
|
2010-06-14 |
2011-12-22 |
国立大学法人山口大学 |
乾癬治療効果の経過観察及び早期の予測方法並びにそれらに使用するキット
|